Literature DB >> 15138809

Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome.

Sabine Dormann1, Marcus Krüger, Roland Hentschel, Regina Rasenack, Brigitte Strahm, Udo Kontny, Charlotte Niemeyer.   

Abstract

UNLABELLED: Neonates with Down syndrome can present with a haematological disorder called transient abnormal myelopoiesis (TAM). While TAM is usually a self-limiting disease, patients with severe complications such as hydrops fetalis, cardiorespiratory failure and liver fibrosis have been described. Here, we present five consecutive neonates with trisomy 21 and TAM, four of whom were critically ill and were therefore treated with cytosine-arabinoside. All five patients survived.
CONCLUSION: severely affected neonates with Down syndrome and transient abnormal myelopoiesis might benefit from early cytostatic treatment with cytosine-arabinoside. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138809     DOI: 10.1007/s00431-004-1452-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study.

Authors:  Fawaz Al-Kasim; John J Doyle; Gita V Massey; Howard J Weinstein; Alvin Zipursky
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

Review 2.  Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome.

Authors:  A Zipursky; E J Brown; H Christensen; J Doyle
Journal:  Clin Lab Med       Date:  1999-03       Impact factor: 1.935

3.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

Review 4.  Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis.

Authors:  M Schwab; C Niemeyer; U Schwarzer
Journal:  Med Pediatr Oncol       Date:  1998-09

Review 5.  Leukemia in Down syndrome: a review.

Authors:  A Zipursky; A Poon; J Doyle
Journal:  Pediatr Hematol Oncol       Date:  1992 Apr-Jun       Impact factor: 1.969

6.  Thrombopoietin level is inversely related to blast count, not platelet number, in Down syndrome neonates with transient myeloproliferative disorder.

Authors:  M Bonno; E Azuma; H Kawasaki; X L Zhang; Y Komada; M Hirayama; M Higashigawa; M Umemoto; T Koike; T Kato; T Tahara; H Miyazaki; M Sakurai
Journal:  Am J Hematol       Date:  1998-08       Impact factor: 10.047

7.  Acute megakaryocytic leukemia (AMKL) with major myelofibrosis in an infant. Diagnosis by liver biopsy and response to treatment.

Authors:  D Garel; F Mielot; P Gaulard; J Quillard; J P Dommergues; G Tchernia
Journal:  Nouv Rev Fr Hematol       Date:  1991

8.  Characterization of the blast cell population in two neonates with Down's syndrome and transient myeloproliferative disorder.

Authors:  L Coulombel; M Derycke; J L Villeval; C Leonard; J Breton-Gorius; M Vial; P Bourgeois; G Tchernia
Journal:  Br J Haematol       Date:  1987-05       Impact factor: 6.998

Review 9.  Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome.

Authors:  N Yagihashi; K Watanabe; S Yagihashi
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

Review 10.  Clonal hematologic disorders in Down syndrome. A review.

Authors:  H Avet-Loiseau; F Mechinaud; J L Harousseau
Journal:  J Pediatr Hematol Oncol       Date:  1995-02       Impact factor: 1.289

View more
  3 in total

1.  Common atrioventricular valvular regurgitation as a cause of hydrops fetalis in Down syndrome.

Authors:  Nobuhiro Hidaka; Yoshihide Chiba
Journal:  J Med Ultrason (2001)       Date:  2007-09-14       Impact factor: 1.314

2.  Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.

Authors:  Carla L Pennella; Tamara Muñoz Cassina; Jorge G Rossi; Edgardo M Baialardo; Patricia Rubio; María A Deu; Luisina Peruzzo; Myriam R Guitter; Cristian G Sanchez de La Rosa; Elizabeth M Alfaro; María S Felice
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

Authors:  Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.